Use of a Continuous Glucose Sensor in an Extracorporeal Life Support Circuit

Abstract

Background:

Standard care for infants on extracorporeal life support (ECLS) relies on intermittent measurement of blood glucose (BG); however, this can lead to significant changes in BG that go unrecognized for several hours. The present study was designed to assess performance and clinical applicability of a subcutaneous glucose sensor technology modified for use as a blood-contacting sensor within the ECLS circuit.

Methods:

Twelve children, aged 3 years or less, requiring ECLS support were studied. Three continuous glucose sensors (Medtronic MiniMed) were inserted into hubs placed in line with the ECLS circuit. Blood glucose was assessed with a laboratory analyzer (BG _LAB; Bayer Rapidlab 860) approximately every 5 h (mean 4.9 ± 3.3 h) with more frequent samples obtained with a bedside monitor (HemoCue) as needed. Sensor current (I _SIG) was transmitted to a laptop computer and retrospectively calibrated using BG _LAB. Sensor performance was assessed by mean absolute relative difference (MARD), linear regression slope and intercept, and correlation, all with BG _LAB as reference.

Results:

The BG _LAB averaged 107.6 ± 36.4 mg/dl (mean ± standard deviation) ranging from 58 to 366 mg/dl. The MARD was 11.4%, with linear regression slope (0.86 ± 0.030) and intercept (9.0 ± 3.2 mg/dl) different from 1 and 0, respectively (p < .05), and correlation (r ² = 0.76; p < .001). The system was not associated with any adverse events, and placement and removal into the hubs was easily accomplished. Instances in which more frequent BG values were obtained using a bedside HemoCue (BG _HEMO) monitor showed the sensor to respond rapidly to changes.

Conclusions:

We conclude that continuous sensors can be adapted for use in an ECLS circuit with accuracy similar to or better than that achieved with the subcutaneous site. Continuous glucose monitoring in this population can rapidly detect changes in BG that would not otherwise be observed. Further studies will be needed to assess the benefit of continuous glucose monitoring in this population.

Keywords

cardiopulmonary bypass continuous monitor extracorporeal extracorporeal life support glucose

References

Conrad

Rycus

Dalton

. Extracorporeal Life Support Registry Report 2004. ASAIO J. 2005; 51 (1): 4–10.

Kyle

Jolliet

Genton

Meier

Mensi

Graf

Chevrolet

Pichard

. Clinical evaluation of hormonal stress state in medical ICU patients: A prospective blinded observational study. Intensive Care Med. 2005; 31 (12): 1669–75.

Glass

Wagner

Papero

Rajasingham

Civitello

Kjaer

Coffman

Getson

Short

. Neurodevelopmental status at age five years of neonates treated with extracorporeal membrane oxygenation. J Pediatr. 1995; 127 (3): 447–57.

Short

. The effect of extracorporeal life support on the brain: A focus on ECMO. Semin Perinatol. 2005; 29 (1): 45–50.

Renard

Costalat

Chevassus

Bringer

. Artificial beta-cell: Clinical experience toward an implantable closed-loop insulin delivery system. Diabetes Metab. 2006; 32 (5 Pt 2): 497–502.

Javid

Halwick

Betit

Thompson

Long

Zhang

Jaksic

Agus

. The first use of live continuous glucose monitoring in patients on extracorporeal life support. Diabetes Technol Ther. 2005; 7 (3): 431–9.

Steil

Rebrin

Mastrototaro

Bernaba

Saad

. Determination of plasma glucose during rapid glucose excursions with a subcutaneous glucose sensor. Diabetes Technol Ther. 2003; 5 (1): 27–31.

Steil

Rebrin

Hariri

Jinagonda

Tadros

Darwin

Saad

. Interstitial fluid glucose dynamics during insulin-induced hypoglycaemia. Diabetologia. 2005; 48 (9): 1833–40.

Steil

Rebrin

Darwin

Hariri

Saad

. Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes. 2006; 55 (12): 3344–50.

10.

Panteleon

Rebrin

Steil

. The role of the independent variable to glucose sensor calibration. Diabetes Technol Ther. 2003; 5 (3): 401–10.

11.

Keenan

Cartaya

Mastrototaro

. Accuracy of a new real-time continuous glucose monitoring algorithm. J Diabetes Sci Technol. 2010; 4 (1): 111–8.

12.

Rebrin

Sheppard

Jr Steil

. Use of subcutaneous interstitial fluid glucose to estimate blood glucose: Revisiting delay and sensor offset. J Diabetes Sci Technol. 2010; 4 (5): 1087–98.

13.

Henninger

Woderer

Kloetzer

Staib

Gillen

Gretz

Kraenzlin

Pill

. Tissue response to subcutaneous implantation of glucose-oxidase-based glucose sensors in rats. Biosens Bioelectron. 2007; 23 (1): 26–34.

14.

Chen

Schmidtke

Heller

. Defining the period of recovery of the glucose concentration after its local perturbation by the implantation of a miniature sensor. Clin Chem Lab Med. 2002; 40 (8): 786–9.

15.

Monsod

Flanagan

Rife

Saenz

Caprio

Sherwin

Tamborlane

W V

. Do sensor glucose levels accurately predict plasma glucose concentrations during hypoglycemia and hyperinsulinemia? Diabetes Care. 2002; 25 (5): 889–93.

16.

Voskanyan

Keenan

D Barry

Mastrototaro

Steil

. Putative delays in interstitial fluid (ISF) glucose kinetics can be attributed to the glucose sensing systems used to measure them rather than the delay in ISF glucose itself. J Diabetes Sci Technol. 2007; 1 (5): 639–44.

17.

Stout

Racchini

Hilgers

. A novel approach to mitigating the physiological lag between blood and interstitial fluid glucose measurements. Diabetes Technol Ther. 2004; 6 (5): 635–44.

18.

Youssef

Castle

Engle

Massoud

Ward

. Continuous glucose monitoring in subjects with type 1 diabetes: Improvement in accuracy by correcting for background current. Diabetes Technol Ther. 2010; 12 (11): 921–8.

19.

Agus

Javid

Ryan

Jaksic

. Intravenous insulin decreases protein breakdown in infants on extracorporeal membrane oxygenation. J Pediatr Surg. 2004; 39 (6): 839–44.

20.

Agus

Javid

Piper

Wypij

Duggan

Ryan

Jaksic

. The effect of insulin infusion upon protein metabolism in neonates on extracorporeal life support. Ann Surg. 2006; 244 (4): 536–44.

21.

Doenst

Wijeysundera

Karkouti

Zechner

Maganti

Rao

Borger

. Hyperglycemia during cardiopulmonary bypass is an independent risk factor for mortality in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg. 2005; 130 (4): 1144.

22.

Furnary

Bookin

. Effect of hyperglycemia and continuous intravenous insulin infusions on outcomes of cardiac surgical procedures: The Portland Diabetic Project. Endocr Pract. 2004; 10 Suppl 2: 21–33.

23.

Najmaii

Redford

Larson

. Hyperglycemia as an effect of cardiopulmonary bypass: Intra-operative glucose management. J Extra Corpor Technol. 2006; 38 (2): 168–73.

24.

Preissig

Rigby

. Pediatric critical illness hyperglycemia: Risk factors associated with development and severity of hyperglycemia in critically ill children. J Pediatr. 2009; 155 (5): 734–9.

25.

Carvalho

Moore

Qizilbash

Lachapelle

Schricker

. Maintenance of normoglycemia during cardiac surgery. Anesth Analg. 2004; 99 (2): 319–24.

26.

Chaney

Nikolov

Blakeman

Bakhos

. Attempting to maintain normoglycemia during cardiopulmonary bypass with insulin may initiate postoperative hypoglycemia. Anesth Analg. 1999; 89 (5): 1091–5.

27.

Smith

Styn

Kalhan

Pinchak

Gill

Kramer

Sidhu

. Intraoperative glucose control in diabetic and nondiabetic patients during cardiac surgery. J Cardiothorac Vasc Anesth. 2005; 19 (2): 201–8.

28.

Brunkhorst

Engel

Bloos

Meier-Hellmann

Ragaller

Weiler

Moerer

Gruendling

Oppert

Grond

Olthoff

Jaschinski

John

Rossaint

Welte

Schaefer

Kern

Kuhnt

Kiehntopf

Hartog

Natanson

Loeffler

Reinhart

, German Competence Network Sepsis (SepNet). Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med. 2008; 358 (2): 125–39.